Body weight in youth associated with NHL in adulthood
According to a poster presentation at the American Association for Cancer Research Frontiers in Cancer Prevention Research, there is a link between body weight in young adulthood and cancer later in life.
Using data from the Nurse's Health Study (NHS) and the Health Professionals’ Follow-Up Study (HPFS), researchers from Harvard found an association between obesity in both men and women between the ages of 18-21 and development of non-Hodgkin's lymphoma later in life.
Obesity in this case was defined as having a BMI of 30 or higher. The link between the two was far more prominent in men than in women.
Obese men had a 64 percent higher risk of developing NHL than peers who were not obese. In women this higher risk was 19 percent.
The Nurse's Health Study (NHS) followed over 91,000 women for 28 years. The Health Professionals’ Follow-Up Study (HPFS) followed over 47,000 men for 22 years.
Source
AACR in the news: Body Weight, Diet May Be Risk Factors for Non-Hodgkin Lymphoma
More Articles
More Articles
Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...
The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...
Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...
At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...
Site Beginnings
This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...
Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...
The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...
The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...
The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...
According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...
Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...
New research suggests that frontline radioimmunotherapy...
Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...
